Life sciences company Thermo Fisher (NYSE: TMO) reported revenue ahead of Wall Streets expectations in Q4 CY2025, with sales up 7.2% year on year to $12.22 billion. Its non-GAAP profit of $6.57 per share was 1.9% above analysts’ consensus estimates.

Is now the time to buy TMO? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Thermo Fisher’s fourth quarter results exceeded Wall Street’s top-line and non-GAAP profit expectations, yet the market responded negatively, reflecting investor concerns beyond headline beats. Management highlighted robust growth in bioproduction, steady performance in clinical research, and continued momentum in pharma and biotech customer segments as key drivers. CEO Marc Casper attributed the quarter’s revenue strength to high-impact product launches—such as the Orbitrap Astro Zoom mass spectrometer and DynaDrive bioreactor—and the company’s ability to manage tariff headwinds and policy dynamics. He acknowledged that academic and industrial end markets remained pressured, particularly in the U.S. and China.

Looking ahead, Thermo Fisher’s guidance is underpinned by expectations of steady market conditions, ongoing innovation, and incremental benefits from recent acquisitions. Management emphasized that growth in 2026 will depend on continued demand from pharma and biotech, successful integration of new assets like Clario, and operational improvements enabled by its productivity system. Casper stated, “We are initiating a 2026 revenue guidance range of $46.3 billion to $47.2 billion, which represents 4% to 6% reported revenue growth over 2025.” CFO Stephen Williamson noted that the outlook assumes cautious academic and government spending and that any upside would come from a recovery in funding or accelerated pharma activity.

Key Insights from Management’s Remarks

Management attributed the quarter’s revenue growth to strong bioproduction and clinical research demand, new product launches, and benefits from recent acquisitions, while noting ongoing cost pressures from tariffs and macro uncertainty.

• Bioproduction business momentum: Thermo Fisher’s bioproduction segment delivered high single-digit growth, with management crediting strong customer demand for single-use technologies and expanded manufacturing solutions. New product launches, such as the DynaDrive single-use bioreactor, were cited as key differentiators.

• Clinical research recovery: The company saw mid-single-digit growth in its clinical research business, driven by increased outsourcing and adoption of the integrated Accelerator solution, Thermo Fisher’s branded integrated CDMO and CRO offering, which streamlines drug development and speeds time to market for pharmaceutical clients.

• Innovation pipeline expansion: Management highlighted the launch of several high-impact products, including the Orbitrap Astro Zoom mass spectrometer and the Helios MX-one plasma focused ion beam SEM, which are strengthening Thermo Fisher’s leadership in analytical instruments and life sciences research tools.

• Impact of M&A activity: Recent acquisitions, including the filtration and separation business from Sorventum, Sanofi’s fill-finish site, and the pending Clario deal, were described as enhancing capabilities in bioproduction, pharma services, and clinical research. Management expects these moves to contribute to both revenue and margin accretion over time, despite some near-term margin dilution from integration investments.

• Tariff and cost headwinds: CFO Stephen Williamson noted that tariffs and related foreign exchange pressures weighed on margins, particularly in the analytical instruments segment. Despite these headwinds, operational efficiencies and disciplined cost management partially offset the impact.

Drivers of Future Performance

Thermo Fisher’s 2026 outlook hinges on sustained pharma and biotech demand, benefits from recent acquisitions, and prudent cost management amid cautious academic and government spending.

• Pharma and biotech demand: Management expects continued growth in pharma and biotech, with a particular focus on sterile fill-finish capacity and clinical research outsourcing. CEO Marc Casper pointed to a positive funding environment for biotech and strong pipelines at pharma customers as supportive factors, though he cautioned that a lag exists between new funding and actual spending.

• Integration of acquisitions: The pending Clario acquisition and recent deals are expected to enhance Thermo Fisher’s capabilities in digital clinical endpoints and drug manufacturing. The company anticipates these assets will support higher organic growth and margin expansion over the next several years, although near-term integration costs may weigh on results.

• Cautious academic/government outlook: Management is modeling for flat to slightly up academic and government funding, acknowledging persistent caution among customers due to budget uncertainties. Casper noted that any improvement in NIH or global grant funding could provide upside, but the company is not relying on it for its baseline guidance.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will monitor (1) the pace of pharma and biotech funding translating into increased spending, (2) integration milestones and revenue contribution from recent acquisitions like Clario, and (3) any signs of recovery in academic and government end markets, especially following U.S. budget developments. Execution in product innovation and operational efficiencies will also be key to sustaining margin performance.

Thermo Fisher currently trades at $594, down from $608.02 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).

High Quality Stocks for All Market Conditions

Your portfolio can’t afford to be based on yesterday’s story. The risk in a handful of heavily crowded stocks is rising daily.

The names generating the next wave of massive growth are right here in our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.